Covid: Natco Pharma seeks
approval for Molnupiravir
capsules phase 3 trials
Natco Pharma Limited on Monday said it applied to the Central
Drugs Standard Control Organization (CDSCO) for approval of
Phase-III clinical trial of Molnupiravir Capsules for the treatment
of COVID-19 positive patients.
American pharma major Merck along with Ridgeback
Biotherapeutics has developed Molnupiravir(MK-4482).
According to a press release from the city-based drug maker, pre-
clinical data have shown that Molnupiravir has broad anti-
influenza activity, including highly potent inhibition of SARS-CoV-
"Patients treated with Molnupiravir achieved response within 5
days of therapy indicating that the duration of treatment with
Molnupiravir is short, with the additional advantage of being an
oral therapy," it said.
NATCO is hoping that CDSCO would give emergency approval of
this drug based on "compassionate use" for patients. Read More